Skip to main content

Europe Genome Editing Market to Grow at 16.7+% CAGR to Reach US$ 3,421.1 Million by 2025 Led by Transposagen Biopharmaceuticals, Integrated DNA Technologies, Thermo Fisher Scientific, GenScript

Press release   •   Apr 18, 2019 10:36 IST

Europe Genome Editing Market to 2025

The Europe genome editing market accounted to US$ 1,052.9 Mn in 2017 and is expected to grow at a CAGR of 16.7% during the forecast period 2018 – 2025, to account to US$ 3,421.1 Mn by 2025.

The Asia Pacific genome editing market is expected to grow at highest rate during the forecast period owing to increasing investments by the governments of the respective countries in the region. In addition, the rise in the development and research for the genome editing along with the clinical trials are expected to fuel the market growth in Asia Pacific region.

Europe Genome Editing Market research report is a detailed analysis of the current situation of the industry. An insight study of Europe Genome Editing Market done by an industry professional and market experts. This report brings company information, volume, product scope, cost and price of production, profit, demand-supply, import-export activities as well as consumption. It provides the essential marketing methods that cover driving factors, market constraints, opportunities, huge challenges, market share, key players as well as top growing regions.

Ask for a Sample of this Report Now at: http://bit.ly/2IDLtrS

Key Benefits:

  • To provide detailed information regarding the major factors (drivers, restraints, opportunities, challenges, and trends) influencing the growth of the global Europe Genome Editing Market
  • To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (Latin America and the Middle East & Africa)

Some of the Major Players In Europe Genome Editing Market:

  • Transposagen Biopharmaceuticals, Inc.
  • Integrated DNA Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • GenScript
  • Lonza
  • Horizon Discovery Group plc
  • Sangamo Therapeutics, Inc.
  • New England Biolabs
  • Editas Medicine
  • Merck KGaA

Europe Genome Editing Market report aims to provide a 360-degree view of the market in terms of cutting-edge technology, key developments, drivers, restraints and future trends with impact analysis of these trends on the market for short-term, mid-term and long-term during the forecast period. Further, the report also covers key players profiling with detailed SWOT analysis, financial facts and key developments of products/service from the past three years.

The Europe genome editing market on the basis of application is segmented into genetic engineering, cell line engineering and others. The cell line engineering segment is anticipated to grow at a CAGR of 17.5% during the forecast period. Moreover, the genetic engineering segment is expected to grow at the significant rate during the coming years owing to its sub segments such as animal genetic engineering and plant genetic engineering that are being carried out extensively.

Strategic Insights

Strategic acquisition and product launches were observed as the most adopted strategy in Europe genome editing industry. Few of the recent product launch and product approval are listed below:

2018: Thermo Fisher Scientific announced the acquisition of IntegenX. IntegenX has been developing rapid DNA testing technology for human identification for use in forensics and law enforcement. The company in 2015, has launched RapidHIT System, which is the first-generation STR-based human identification system that is also compatible with Thermo Fisher's STR kits.

2017: Integrated DNA Technologies announced the product launch of variants of the first Cas9 enzyme. These are used for extensive reduction off-target effects in CRISPR genome editing and does not compromise on-target activity. The Alt-R S.p. HiFi Cas9 Nuclease 3NLS enzyme is a recombinant S. pyogenes Cas9 mutant improvises the specificity and also maintenance a high editing efficiency similar to wild-type Cas9.

2016: GenScript announced the launch of its new service CRISPR based Yeast Genome Editing Service. The service utilizes the λ Red-CRISPR/Cas9 technology.

Besides this, the report analyzes factors affecting market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South America after evaluating political, economic, social and technological factors effecting the market in these regions.

EUROPE GENOME EDITING – MARKET SEGMENTATION

By Technology

  • TALENS
  • CRISPR
  • Zinc Finger Nucleases (ZFNs)
  • Others

By Application

  • Genetic Engineering
    • Animal Genetic Engineering
    • Plant Genetic Engineering
  • Cell Line Engineering
  • Others

By End User

  • Biotechnology & Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic & Government Research Institutes

By Geography

  • Europe
    • U.S.
    • Canada
    • Mexico
  • Inquiry for Discount: http://bit.ly/2UI1DYy

    About Us
    The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

    We are committed to providing highest quality research and consulting services to our customers. We help our clients understand key market trends, identify opportunities, and make informed decisions by providing market research solutions at an affordable cost.

    Contact us

    The Insight partners,
    Phone: +1-646-491-9876

    Email: sales@theinsightpartners.com

    Home: https://www.theinsightpartners.com

    Comments (0)

    Add comment

    Comment

    By submitting the comment you agree that your personal data will be processed according to Mynewsdesk's Privacy Policy.